CO5640075A2 - Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas - Google Patents

Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas

Info

Publication number
CO5640075A2
CO5640075A2 CO05119657A CO05119657A CO5640075A2 CO 5640075 A2 CO5640075 A2 CO 5640075A2 CO 05119657 A CO05119657 A CO 05119657A CO 05119657 A CO05119657 A CO 05119657A CO 5640075 A2 CO5640075 A2 CO 5640075A2
Authority
CO
Colombia
Prior art keywords
alkyl
pharmaceutical composition
hydrogel
active substances
transdermal administration
Prior art date
Application number
CO05119657A
Other languages
English (en)
Inventor
Franke Patrick
Kuhnz Wilhelm
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33395772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5640075(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO5640075A2 publication Critical patent/CO5640075A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

1.- Composición farmacéutica en forma de hidrogel que contiene un diéster de ácido carboxílico, un alquilalcohol-C2-C4, por lo sustancia activa y una matriz depolímero.2.- Composición de acuerdo con la reivindicación 1, CARACTERIZADA PORQUE, el diéster de ácido carboxílico es un compuesto de la fórmula general (I) Donde (i) R1 y R2 son, en cada caso, alquil-C1-C6, alquenilo-C2-C6-, alquinilo-C2-C6, cicloalquilo-C4-C6, heterocicloalquilo-C1-C6, fenilo, heretoarilo-C1-C6, fenil-alquilo-C1-C4 o heteroarilalquilo-C2-C10, donde los grupos alquilo-, alquenilo- y alquinilo pueden estar interrumpidos cada vez, hasta tres veces por átomos de oxógeno y/o átomos de azufre, o R1 y R2 tienen, en cada caso, uno de los significados indicados más arriba y están unidos entre sí por medio de una unión C-C.
CO05119657A 2003-04-28 2005-11-25 Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas CO5640075A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03008856 2003-04-28

Publications (1)

Publication Number Publication Date
CO5640075A2 true CO5640075A2 (es) 2006-05-31

Family

ID=33395772

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05119657A CO5640075A2 (es) 2003-04-28 2005-11-25 Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas

Country Status (33)

Country Link
EP (2) EP1617827B1 (es)
JP (2) JP4829102B2 (es)
KR (1) KR101093999B1 (es)
CN (1) CN1780610B (es)
AR (1) AR044113A1 (es)
AT (2) ATE467412T1 (es)
AU (1) AU2004233572B2 (es)
BR (1) BRPI0409918A (es)
CA (1) CA2523734C (es)
CL (1) CL2004000884A1 (es)
CO (1) CO5640075A2 (es)
CR (1) CR8059A (es)
CY (1) CY1108069T1 (es)
DE (2) DE502004006196D1 (es)
DK (1) DK1617827T3 (es)
EA (1) EA008686B1 (es)
EC (1) ECSP056186A (es)
ES (2) ES2300763T3 (es)
HK (1) HK1087633A1 (es)
HR (1) HRP20080178T3 (es)
JO (1) JO2492B1 (es)
MX (1) MXPA05011541A (es)
NO (1) NO20055601L (es)
NZ (2) NZ583760A (es)
PE (1) PE20050461A1 (es)
PL (1) PL1617827T3 (es)
PT (1) PT1617827E (es)
RS (1) RS51307B (es)
SI (1) SI1617827T1 (es)
TW (1) TWI343259B (es)
UA (1) UA83036C2 (es)
WO (1) WO2004096191A1 (es)
ZA (1) ZA200509549B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0506141D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
GB0506139D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A transdermal topical composition and its uses
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
DE102005035879A1 (de) * 2005-07-30 2007-02-01 Paul Hartmann Ag Hydrogel
SE536091C2 (sv) * 2011-04-14 2013-04-30 Pep Tonic Medical Ab Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
WO2012148174A2 (ko) * 2011-04-25 2012-11-01 Park Jun-Hyoung 탈모방지 및 발모촉진용 외용제 조성물
FR2976808B1 (fr) * 2011-06-22 2013-06-28 Urgo Lab Composition filmogene et son utilisation pour le traitement de l'herpes
US9855211B2 (en) * 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
DE102018213754A1 (de) * 2018-08-15 2020-02-20 Henkel Ag & Co. Kgaa "Tris(hydroxymethyl-)aminomethan oder seine Salze als Wirkstoff zur Reduzierung der Schweißsekretion“

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341557A (en) 1961-06-05 1967-09-12 Upjohn Co 7-methyltestosterones
DE1182229B (de) 1960-11-16 1964-11-26 Upjohn Co Verfahren zur Herstellung von 7-Methylsteroiden
US3924004A (en) 1971-11-24 1975-12-02 Syntex Corp Fatty alcohol-propylene carbonate-glycol solvent cream vehicle
US4000273A (en) 1973-11-01 1976-12-28 Richardson-Merrell Inc. Method for the control of fertility
JPS5540604A (en) * 1978-09-14 1980-03-22 Mitsui Toatsu Chem Inc Improved local topicum
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
JPS5970612A (ja) * 1982-10-13 1984-04-21 Nippon Redarii Kk ゲル軟膏基剤
JPH01503281A (ja) * 1987-05-27 1989-11-09 ブルグハルト，クルト 経皮治療に有効な医薬包帯剤およびこれを施用するためのデバイス
HU210549B (en) * 1988-10-27 1995-05-29 Schering Ag Process for producing transdermally applicable pharmaceutical composition containing gestodene
AU677206B2 (en) * 1992-06-11 1997-04-17 Theratech, Inc. The use of glycerin in moderating transdermal drug delivery
US5460620A (en) * 1992-07-31 1995-10-24 Creative Products Resource, Inc. Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
WO1996008255A1 (en) 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Transdermal device for delivery of levonorgestrel
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
JPH09194396A (ja) 1996-01-17 1997-07-29 Pola Chem Ind Inc 貼付剤用マトリックス
US5733565A (en) 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
US5736128A (en) * 1996-05-14 1998-04-07 Isp Investments Inc. Cosmetic composition for rejuvenation of skin without skin irritation
WO1997043989A1 (en) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US20020012694A1 (en) 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
AU756739B2 (en) 1998-06-19 2003-01-23 N.V. Organon Testosterone derivative
FR2781666B1 (fr) * 1998-07-30 2000-09-08 Oreal Composition cosmetique solide et ses utilisations
JP2935113B1 (ja) * 1998-09-24 1999-08-16 小林製薬株式会社 インドメタシン経皮吸収剤
WO2000041702A1 (fr) 1999-01-13 2000-07-20 Taisho Pharmaceutical Co., Ltd. Preparation steroide externe
JP2000264899A (ja) * 1999-01-13 2000-09-26 Taisho Pharmaceut Co Ltd ステロイド外用剤
JP2001139451A (ja) * 1999-11-17 2001-05-22 Lion Corp ジェル状化粧料
IL156208A0 (en) 2000-12-15 2003-12-23 Akzo Nobel Nv 14 (15)-unsaturated 15-and/or 16-substituted androgens with mixed androgen-progestational profile
DE10104327A1 (de) * 2001-01-24 2002-07-25 Schering Ag 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate
DE10107663B4 (de) 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung

Also Published As

Publication number Publication date
RS51307B (sr) 2010-12-31
NO20055601L (no) 2006-01-26
EP1617827B1 (de) 2008-02-13
NO20055601D0 (no) 2005-11-25
EA200501583A1 (ru) 2006-06-30
MXPA05011541A (es) 2006-05-31
AU2004233572B2 (en) 2010-07-15
DK1617827T3 (da) 2008-06-02
CY1108069T1 (el) 2014-02-12
JP4829102B2 (ja) 2011-12-07
ES2345458T3 (es) 2010-09-23
ZA200509549B (en) 2007-02-28
CN1780610B (zh) 2010-06-09
CL2004000884A1 (es) 2005-03-11
SI1617827T1 (sl) 2008-06-30
KR101093999B1 (ko) 2011-12-15
JP2006524653A (ja) 2006-11-02
CA2523734C (en) 2009-12-22
DE502004006196D1 (de) 2008-03-27
TW200524644A (en) 2005-08-01
NZ543264A (en) 2010-03-26
PT1617827E (pt) 2008-04-30
TWI343259B (en) 2011-06-11
RS20050809A (en) 2007-09-21
ECSP056186A (es) 2006-04-19
BRPI0409918A (pt) 2006-04-25
NZ583760A (en) 2011-10-28
CN1780610A (zh) 2006-05-31
WO2004096191A1 (de) 2004-11-11
EA008686B1 (ru) 2007-06-29
ATE467412T1 (de) 2010-05-15
AU2004233572A1 (en) 2004-11-11
AR044113A1 (es) 2005-08-24
CR8059A (es) 2006-05-29
CA2523734A1 (en) 2004-11-11
JO2492B1 (en) 2009-10-05
HRP20080178T3 (en) 2008-05-31
HK1087633A1 (en) 2006-10-20
JP2010241824A (ja) 2010-10-28
PL1617827T3 (pl) 2008-07-31
EP1875905B1 (de) 2010-05-12
ES2300763T3 (es) 2008-06-16
EP1875905A2 (de) 2008-01-09
DE502004011164D1 (de) 2010-06-24
ATE385786T1 (de) 2008-03-15
UA83036C2 (ru) 2008-06-10
EP1617827A1 (de) 2006-01-25
EP1875905A3 (de) 2008-06-25
KR20060007403A (ko) 2006-01-24
PE20050461A1 (es) 2005-08-13

Similar Documents

Publication Publication Date Title
CO5640075A2 (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
DOP2005000046A (es) Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
AR060991A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo y composiciones farmaceuticas que los contienen utilizadas para el tratamiento de la diabetes
PE20090042A1 (es) Analogos de ciclopamina
ECSP066898A (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
DE60319967D1 (de) Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
AR056511A1 (es) Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4
ECSP066958A (es) Compuestos de morfolina
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
BRPI0918904B8 (pt) formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
PE20161035A1 (es) Compuestos y usos de estos para la modulacion de la hemoglobina
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
PE20080348A1 (es) Moduladores tiazolopirimidina de trpv1
UY32606A (es) Sulfonamidas nematocidas
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
UY29427A1 (es) Derivados sustituidos de 2,3,4,5- tetrahidro-1h-pirido (4,3-b) indol, composiciones que los contienen, procesos de preparación y aplicaciones
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
AR064066A1 (es) Un agente para tratamiento del suelo o agente para el tratamiento de la semilla que comprende compuestos de quinolina o sus sales como un componente activo, o un metodo para prevenir las enfermedades de plantas por el uso de este.
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas

Legal Events

Date Code Title Description
FC Application refused
FG Application granted
FD Application lapsed